Key features and details
- Rabbit polyclonal to Puma gamma/GPR109A
- Suitable for: WB, ICC/IF
- Reacts with: Human
- Isotype: IgG
Product nameAnti-Puma gamma/GPR109A antibody
See all Puma gamma/GPR109A primary antibodies
DescriptionRabbit polyclonal to Puma gamma/GPR109A
Tested applicationsSuitable for: WB, ICC/IFmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to Human Puma gamma/GPR109A aa 250-350 conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in Human liver tissue lysate.
This product was previously labelled as Puma gamma
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
Our Abpromise guarantee covers the use of ab81825 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 41 kDa (predicted molecular weight: 41 kDa).|
|ICC/IF||Use a concentration of 5 µg/ml.|
FunctionActs as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.
Tissue specificityExpression largely restricted to adipose tissue and spleen. Expressed on mature neutrophils but not on immature neutrophils or eosinophils.
Sequence similaritiesBelongs to the G-protein coupled receptor 1 family.
Developmental stageExpression in neutrophils occurs in the late terminal differentiation phase.
Cellular localizationCell membrane.
- Information by UniProt
- G protein coupled receptor 109A antibody
- G protein coupled receptor HM74a antibody
- G protein coupled receptor Hm74b antibody
Anti-Puma gamma/GPR109A antibody (ab81825) at 1 µg/ml + Human liver tissue lysate - total protein (ab29889) at 10 µg
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 41 kDa
Observed band size: 41 kDa
Exposure time: 12 minutes
ICC/IF image of ab81825 stained MCF7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab81825, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 rabbit anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
ab81825 has been referenced in 1 publication.
- Zhou D et al. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Exp Mol Med 50:157 (2018). PubMed: 30510243